Den-Mat Holdings Recalls 10,103 Units of Hydrogen Peroxide Oral Rinse Over CGMP Deviations
Den-Mat Holdings, LLC has initiated a Class II recall for 10,103 units of Hydrogen Peroxide Oral Rinse due to Current Good Manufacturing Practice (CGMP) deviations, impacting product specifications. This event, recall number D-0287-2024, necessitates immediate action from procurement and supply chain leaders to assess inventory and mitigate potential market disruptions.
FDA Identifies CGMP Deviations in Den-Mat Holdings' Oral Rinse Recall
Den-Mat Holdings, LLC, operating from its facility in Lompoc, California, has initiated a Class II voluntary recall of its Hydrogen Peroxide Oral Rinse, a product marketed for significantly reducing bacteria with a fresh mint flavor and alcohol-free formulation. The core issue, as identified by the FDA, stems from Current Good Manufacturing Practice (CGMP) deviations, which indicate that the affected products may not conform to their labeled specifications. This regulatory action, designated recall number D-0287-2024, commenced on January 16, 2024, with the FDA classifying it on January 31, 2024. For procurement directors, this signifies a direct challenge to product quality assurance and supplier reliability. The non-conformance to labeled specifications implies that the product may not deliver its intended therapeutic or prophylactic effects, potentially leading to efficacy concerns or, in a Class II scenario, temporary or medically reversible adverse health consequences, or a remote probability of serious adverse health consequences. Regulatory affairs heads must immediately assess the implications of these CGMP deviations, ensuring that all distributed units are accounted for and that the firm's corrective actions align with FDA expectations. This event underscores the critical importance of stringent quality control throughout the manufacturing process to uphold product integrity and consumer safety.
Specific Products and Volume Impacted by Den-Mat Holdings' Recall
The recall encompasses a substantial volume of Den-Mat Holdings' Hydrogen Peroxide Oral Rinse, totaling 10,103 units distributed nationwide across the United States. Specifically, the affected products include three distinct sizes: the 16 fl. oz. (473 mL) bottle, identified by NDC 59883-202-16 and UPC 3 59883 00009 7; the 64 fl. oz. (1.89 L) bottle, with NDC 59883-202-64; and the larger 128 fl. oz. (1 gal) 3.78L bottle, bearing NDC 59883-202-28 and UPC 3 59883 00007 3. Multiple lot numbers across these sizes are implicated, with expiry dates ranging from February 2024 through December 2025. For supply chain VPs, this detailed product information is crucial for precise inventory management and effective recall execution. The nationwide distribution pattern means that the impact is geographically widespread, requiring a coordinated effort to retrieve affected stock from various retail and distribution points. Business development executives should note the potential for brand erosion and market share shifts, as customers and partners may seek more reliable alternatives in the oral care segment. The specific identification of lot numbers and expiry dates facilitates targeted removal from the market, minimizing broader disruption but highlighting the need for robust batch control systems.
Supply Chain Exposure and Commercial Risks for Den-Mat Partners
The voluntary Class II recall initiated by Den-Mat Holdings, LLC presents significant supply chain exposure and commercial risks for any entity involved in the distribution or sale of their Hydrogen Peroxide Oral Rinse. With 10,103 units distributed nationwide, procurement directors must immediately quarantine and return all affected inventory, incurring costs related to logistics, storage, and potential write-offs. The financial implications extend beyond direct costs, encompassing potential lost sales, damage to retailer-consumer relationships, and the administrative burden of managing a recall. Supply chain VPs must activate their recall protocols, ensuring complete traceability of the product from the Lompoc, CA facility to the end-user. This incident underscores the necessity of robust supplier qualification processes that include rigorous audits of CGMP compliance and quality management systems. Companies relying on Den-Mat for oral care products should re-evaluate their risk exposure and consider diversifying their supplier base to mitigate future disruptions. The firm-initiated nature of the recall indicates Den-Mat's proactive response, yet the underlying CGMP issues demand thorough investigation and remediation to restore confidence across the supply chain.
Strategic Sourcing: Identifying Alternatives for Hydrogen Peroxide Oral Rinses
In light of Den-Mat Holdings, LLC's recall of Hydrogen Peroxide Oral Rinse, procurement teams must proactively assess their sourcing strategies for similar oral care products. While our intelligence graph does not currently list specific alternative suppliers for Den-Mat's product, this event serves as a critical reminder for procurement directors to identify and qualify diverse sources for essential chemical and life science ingredients and finished goods. Relying on a single supplier, especially for products with nationwide distribution, significantly amplifies risk when regulatory actions occur. Businesses should prioritize manufacturers with demonstrable histories of strong CGMP compliance and robust quality control systems. Geographically diverse suppliers can also offer resilience against localized disruptions. The qualification timeline for new suppliers, particularly for drug products or ingredients, can be extensive, often spanning several months for audits, documentation review, and sample testing. Therefore, initiating this process now is imperative to prevent future supply gaps and maintain market presence. Business development executives should explore partnerships with manufacturers known for their consistent adherence to FDA standards, safeguarding product availability and brand reputation.
Broader Regulatory Environment: Heightened FDA Scrutiny on Quality Systems
This recall by Den-Mat Holdings, LLC, while specific to CGMP deviations in an oral rinse, occurs within a broader landscape of heightened FDA scrutiny across the chemical and life sciences industries. Recent parallel events highlight the agency's unyielding focus on quality and compliance. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures, and Amgen's Tavneos market future was scrutinized during an FDA hearing concerning independent data review. These incidents, though distinct from Den-Mat's situation, collectively signal an environment where regulatory affairs heads must anticipate rigorous enforcement of manufacturing standards. The FDA's consistent oversight, whether for sterility, product specifications, or data integrity, underscores that any deviation from established CGMP can trigger significant regulatory action. This trend mandates that all manufacturers, from active pharmaceutical ingredient (API) producers to finished product formulators, continuously invest in and audit their quality management systems. Proactive compliance measures are no longer merely best practice but a commercial imperative to avoid costly recalls, import alerts, and reputational damage that can severely impact business continuity and market access.
Remediation Pathways and Future Compliance Outlook for Den-Mat Holdings
Following this Class II recall, Den-Mat Holdings, LLC is expected to undertake comprehensive remediation efforts to address the identified CGMP deviations. This typically involves a thorough root cause analysis to pinpoint the exact failures in their manufacturing processes, quality control, or documentation that led to products not conforming to labeled specifications. For regulatory affairs heads, this means preparing detailed corrective and preventive action (CAPA) plans for submission to the FDA, outlining how the firm will rectify the issues and prevent recurrence. Procurement directors and supply chain VPs should anticipate potential temporary disruptions or changes in product availability from Den-Mat as these remediation activities are implemented. The FDA will closely monitor Den-Mat's progress, and a reinspection may be conducted to verify the effectiveness of the corrective actions. Failure to adequately address the CGMP deviations could escalate regulatory consequences, potentially leading to further enforcement actions, including Warning Letters or even an injunction. Business development executives should closely track Den-Mat's compliance trajectory, as sustained quality issues can significantly impair a company's ability to compete and maintain customer trust in the competitive oral care market.